Heme Oxygenase 1 (HO1 or HMOX1 or EC 1.14.14.18) - Pipeline Review, H2 2016

Global Markets Direct’s, ‘Heme Oxygenase 1 (HO1 or HMOX1 or EC 1.14.14.18) - Pipeline Review, H2 2016’, provides in depth analysis on Heme Oxygenase 1 (HO1 or HMOX1 or EC 1.14.14.18) targeted pipeline therapeutics.

The report provides comprehensive information on the Heme Oxygenase 1 (HO1 or HMOX1 or EC 1.14.14.18) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Heme Oxygenase 1 (HO1 or HMOX1 or EC 1.14.14.18) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Heme Oxygenase 1 (HO1 or HMOX1 or EC 1.14.14.18)

The report reviews Heme Oxygenase 1 (HO1 or HMOX1 or EC 1.14.14.18) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Heme Oxygenase 1 (HO1 or HMOX1 or EC 1.14.14.18) targeted therapeutics and enlists all their major and minor projects

The report assesses Heme Oxygenase 1 (HO1 or HMOX1 or EC 1.14.14.18) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Heme Oxygenase 1 (HO1 or HMOX1 or EC 1.14.14.18) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Heme Oxygenase 1 (HO1 or HMOX1 or EC 1.14.14.18)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Heme Oxygenase 1 (HO1 or HMOX1 or EC 1.14.14.18) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Selvita S.A.

Takeda Pharmaceutical Company Limited

Selvita S.A.

Takeda Pharmaceutical Company Limited

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 3

Introduction 4

Global Markets Direct Report Coverage 4

Heme Oxygenase ...

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 3

Introduction 4

Global Markets Direct Report Coverage 4

Heme Oxygenase 1 (HO1 or HMOX1 or EC 1.14.14.18) Overview 5

Therapeutics Development 6

Heme Oxygenase 1 (HO1 or HMOX1 or EC 1.14.14.18) - Products under Development by Stage of Development 6

Heme Oxygenase 1 (HO1 or HMOX1 or EC 1.14.14.18) - Products under Development by Therapy Area 7

Heme Oxygenase 1 (HO1 or HMOX1 or EC 1.14.14.18) - Products under Development by Indication 8

Heme Oxygenase 1 (HO1 or HMOX1 or EC 1.14.14.18) - Pipeline Products Glance 9

Early Stage Products 9

Heme Oxygenase 1 (HO1 or HMOX1 or EC 1.14.14.18) - Products under Development by Companies 10

Heme Oxygenase 1 (HO1 or HMOX1 or EC 1.14.14.18) - Products under Development by Universities/Institutes 12

Heme Oxygenase 1 (HO1 or HMOX1 or EC 1.14.14.18) - Therapeutics Assessment 14

Assessment by Monotherapy/Combination Products 14

Assessment by Mechanism of Action 15

Assessment by Molecule Type 17

Heme Oxygenase 1 (HO1 or HMOX1 or EC 1.14.14.18) - Companies Involved in Therapeutics Development 18

Selvita S.A. 18

Takeda Pharmaceutical Company Limited 19

Heme Oxygenase 1 (HO1 or HMOX1 or EC 1.14.14.18) - Drug Profiles 20

BTZO-2 - Drug Profile 20

Product Description 20

Mechanism Of Action 20

R&D Progress 20

HYCO-1 - Drug Profile 21

Product Description 21

Mechanism Of Action 21

R&D Progress 21

SEL-303 - Drug Profile 22

Product Description 22

Mechanism Of Action 22

R&D Progress 22

Small Molecule to Activate HO-1 for Endothelial Dysfunction, Asthma and Osteoarthritis - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

Small Molecules to Activate HO-1 - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

Heme Oxygenase 1 (HO1 or HMOX1 or EC 1.14.14.18) - Dormant Projects 25

Appendix 27

Methodology 27

Coverage 27

Secondary Research 27

Primary Research 27

Expert Panel Validation 27

Contact Us 27

Disclaimer 28

List of Tables

List of Tables

Number of Products under Development for, H2 2016 6

Number of Products under Development by Therapy Area, H2 2016 7

Number of ...

List of Tables

Number of Products under Development for, H2 2016 6

Number of Products under Development by Therapy Area, H2 2016 7

Number of Products under Development by Indication, H2 2016 8

Comparative Analysis by Early Stage Products, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Products under Development by Companies, H2 2016 11

Number of Products under Investigation by Universities/Institutes, H2 2016 12

Products under Investigation by Universities/Institutes, H2 2016 13

Assessment by Monotherapy/Combination Products, H2 2016 14

Number of Products by Stage and Mechanism of Action, H2 2016 16

Number of Products by Stage and Molecule Type, H2 2016 17

Pipeline by Selvita S.A., H2 2016 18

Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 19

Dormant Projects, H2 2016 25

Dormant Projects (Contd..1), H2 2016 26

List of Figures

List of Figures

Number of Products under Development for, H2 2016 6

Number of Products under Development by Therapy Area, H2 2016 7

Number of ...

List of Figures

Number of Products under Development for, H2 2016 6

Number of Products under Development by Therapy Area, H2 2016 7

Number of Products under Development by Indication, H2 2016 8

Comparative Analysis by Early Stage Products, H2 2016 9

Assessment by Monotherapy/Combination Products, H2 2016 14

Number of Products by Mechanism of Actions, H2 2016 15

Number of Products by Stage and Mechanism of Actions, H2 2016 15

Number of Products by Stage and Molecule Type, H2 2016 17

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports